MedTrace Logo

Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

NCT03061955 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2024-10-04

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and efficacy of concurrent administration of influenza vaccine in patients receiving anti-PD1 immunotherapy (nivolumab or pembrolizumab). This will be a prospective observational study, aiming to assess patient tolerance of treatment, adverse events (incidence, grade, need for hospitalization), incidence of influenza infections, and seroconversion rates.

Conditions

  • Influenza Virus Vaccine Adverse Reaction (Disorder)
  • Influenza
  • Malignancy

Interventions

BIOLOGICAL

influenza vaccination

administration of influenza vaccination

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-01
Primary Completion
2017-03-31
Completion
2019-04-26

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03061955 on ClinicalTrials.gov